88 results about "Photosens" patented technology

The application discloses a photosensitizer conjugate for targeted treatment of tongue squamous cell carcinoma and a preparation method and application thereof, and belongs to the technical field of biological medicines. A novel PROTAC-PDT conjugate Gef-PRO-SS-TPE is synthesized, and the compound connects a PROTAC molecule Gef-PRO targeting EGFR and an AIE photosensitizer TPE derivative through a breakable disulfide bond. On one hand, Gef-PRO can specifically degrade EGFR and block tumor cell proliferation signals; on the other hand, the TPE derivative can generate ROS under light conditions and induce cell apoptosis. More importantly, the disulfide bond can be broken in response to high concentrations of glutathione (GSH) in tumor cells, realizing controllable release of Gef-PRO and TPE molecules, so as to exert a synergistic anti-tumor effect.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The application discloses a kind of strong electron donor triphenylamine modified coumarin dyes, its synthesis method and application;The dye has blue-green light excitation characteristics, the maximum absorption wavelength is 415-425 nm, the maximum emission wavelength is 495-505 nm, and excellent lysosome targeting and positioning ability is shown.It overcomes the problem of low efficiency of traditional coumarin as photosensitizer in molecular structure design, realizes the efficient I type photodynamic effect, can generate active oxygen under light efficiently.In addition, this dye has good cell membrane permeability and low dark toxicity, suitable for biomedical imaging, photodynamic therapy of tumor and other fields.The synthesis method is simple, raw materials are easy to obtain, and the yield is high, suitable for large-scale production.Experiments show that the dye can effectively enrich in cell lysosomes, realize precise killing of cancer cells, and show great potential in cancer diagnosis and treatment integration.

This invention discloses a photoactivated nanoparticle-based drug delivery material for immunoadjuvants, its preparation method, and its applications. The drug delivery material is constructed from photosensitizer monomers, crosslinking monomers, and immunoadjuvant prodrug monomers within a confined space of a nanoemulsion via a copper-free click polymerization reaction to form crosslinked polymer nanoparticles. The nanoparticle size is controllable, and the composition is precisely defined. Under physiological conditions, the drug delivery material exhibits good colloidal stability and high drug loading. Upon near-infrared light irradiation, the generated ROS can cleave the thioketone bonds, causing the nanoparticles to depolymerize and achieving photo-triggered, controllable release of the immunoadjuvant. Under photodynamic action, this drug delivery material efficiently generates reactive oxygen species to induce immunogenic cell death in tumor cells. Simultaneously, the released immunoadjuvant activates the TLR7 / 8 pathway, promotes dendritic cell maturation, and enhances the systemic anti-tumor immune response, thereby inhibiting the growth of tumors in situ and at distant sites, and reducing the risk of metastasis and recurrence.

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

This invention belongs to the field of biomedical functional materials technology, and relates to an antibacterial and healing-promoting photosensitizer, its preparation method, and its uses. The photosensitizer is a defective MIL-88B@MIL-88C composite material, wherein defective MIL-88B serves as the substrate, and MIL-88C grows on the surface and / or in the pores of the defective MIL-88B. This photosensitizer significantly improves the photogenerated carrier separation efficiency, reduces impedance, enhances photocurrent response, and can efficiently generate reactive oxygen species under light irradiation. Antibacterial experiments show that it has excellent bactericidal effects against Staphylococcus aureus, Escherichia coli, and methicillin-resistant Staphylococcus aureus, and is not prone to inducing drug resistance. Simultaneously, this photosensitizer has good biocompatibility, promotes cell migration, and has significant hemostatic function. Animal models show that it can effectively accelerate the healing of skin defects.

This invention discloses a near-infrared cyclic metallic iridium (III) photosensitizer and its synthesis method. The BDP-Ir prepared by the method of this invention can be used at low doses (IC50). 50 =68nM) at low power (10mW·cm) ‑2 It exhibits high photosensitivity under 808nm excitation, successfully solving the problem of sacrificing both excitation wavelength and photosensitivity efficiency; at the same time, its synergistic biomimetic artificial nano-hybrid delivery system can effectively enhance the tumor targeting and immune escape ability of photosensitizers.

Disclosed are novel phenalene-l-one photosensitizers capable of generating singlet oxygen, compositions comprising at least one novel phenalene-l-one photosensitizer, and uses of the novel phenalene-l-one photosensitizers. The compositions are bleaching compositions, comprising at least one phenalene-l-one photosensitizer, at least one persulfate, at least one alkalizing agent and at least one peroxide source. (Formula I)

This invention discloses a nanoparticle-based drug delivery system, MPL@ICC, its synthesis method, and its applications. The MPL@ICC system consists of hollow, porous nano-MnO2, a hydrophilic targeting complex on its surface, and an acid-responsive drug, INH-CA, and a photosensitizer loaded internally. It possesses both targeted transport and controlled release capabilities against human hepatocellular carcinoma cells (HepG2), allowing it to accumulate within these cells and achieve photodynamic therapy (PDT) and free radical-induced immune killing within the tumor. Simultaneously, it directly kills tumor cells and transforms them from non-immunogenic to immunogenic, mediating an anti-tumor immune response and achieving immunogenic cell death (ICD). This overcomes the shortcomings of ICD-induced cancer treatment strategies, which often fail to produce strong and durable therapeutic effects, and does not induce normal cell apoptosis, thus possessing controllability, effectiveness, and safety.

This invention discloses a method for optimizing the parameters of composite nano-photosensitizers used in the preparation of photodynamic microneedles, relating to the field of biomedical technology. The method includes: preparing octahedral Cu₂O nanoparticles and recording synthesis parameters; in-situ loading of sheet-like CuTCPP to obtain CuTCPP@Cu₂O composite nanoparticles and recording loading parameters; mixing the composite particles with a first matrix and a natural small molecule with a second matrix, followed by layered casting and vacuum-assisted filling to prepare a bilayer microneedle test sample; evaluating performance and adjusting synthesis and / or loading parameters accordingly; and preparing the composite nano-photosensitizer with the final parameters after achieving the desired performance. This invention solves the technical problem that existing composite nano-photosensitizers lack an iterative optimization mechanism based on microneedle sample performance feedback in parameter determination, making it difficult to ensure that the final product consistently meets the expected functional standards. It achieves precise locking of photosensitizer synthesis and loading parameters, ensuring that the final product possesses the preset performance characteristics.

This invention belongs to the field of pharmaceutical technology and relates to a composite nanoparticle that synergistically induces ferroptosis and antitumor immune responses, as well as its preparation method. The invention first provides a dihydroartemisinin dimer prodrug or a pharmaceutically acceptable salt thereof with the following structure. Then, composite nanoparticles are prepared using the aforementioned dihydroartemisinin dimer prodrug or its pharmaceutically acceptable salt as the main drug component. The composite nanoparticles are prepared by covalently binding an albumin-manganese dioxide complex and ferritin, while simultaneously co-encapsulating the dihydroartemisinin dimer prodrug or its pharmaceutically acceptable salt and a photosensitizer. The composite nanoparticles prepared by this invention can disrupt the reducing homeostasis of tumor cells by simultaneously enhancing ROS generation and GSH consumption. PDT and CDT synergistically enhance ROS generation, and manganese dioxide can also promote GSH consumption. These composite nanoparticles can significantly improve drug targeting and significantly enhance antitumor activity.

This invention discloses a method for preparing a gradient porous foam structure, comprising: setting a printing layer, wherein the printing layer is covered with a liquid molding material, the molding material being an acousto-photosensitive material, including a thermosetting resin and a photosensitizer; forming a pore structure in the printing layer through photocuring and / or acoustic cavitation; sequentially setting consecutive printing layers to form a continuous pore structure, and several printing layers forming a gradient porous foam structure. This application utilizes photocuring and / or acoustic cavitation to form a gradient porous foam structure in the printing layer, exhibiting multi-level pore sizes, multi-level porosities, gradient pore sizes, gradient porosities, and combinations of ordered and disordered pores. This allows for continuous spatial molding without assembly, offering advantages such as simple operation, high molding efficiency, and high molding precision.

The application provides a thionaphthimidyl organic antibacterial photosensitizer, a preparation method and application thereof, and belongs to the field of photosensitizers and antibacterial photodynamic therapy; the thionaphthimidyl compound has the following general formula: The thionaphthimidyl organic antibacterial photosensitizer provided by the application has high efficient photodynamic properties and bacterial targeting ability; the photosensitizer has high photosensitization ability and high singlet oxygen yield, and can be specifically enriched on the surface of bacteria (such as MRSA and VISA), and a large amount of active oxygen is generated under light, so that the bacteria can be efficiently killed. The photosensitizer has no obvious toxicity to normal cells at an effective treatment concentration, and has a strong application prospect in antibacterial photodynamic therapy.

This invention discloses a photosensitizer with twisted π-conjugated charge transfer properties, its preparation method, and its applications. The preparation method of the photosensitizer includes the following steps: dissolving a quinolino[3,2,1-de]acridin-5,9-dione derivative, a perylene diimide with brominated position, and a basic substance in a first solvent to obtain a mixture; reacting a palladium catalyst with the mixture under a protective atmosphere; and after the reaction, extracting and purifying to obtain the photosensitizer with twisted π-conjugated charge transfer properties. The photosensitizer prepared by this invention uses a perylene diimide photoabsorbent group as an electron acceptor, which is then coupled with an electron donor group through a ring-closure reaction to prepare a photosensitizer with a twisted π-conjugated structure. The compound prepared by this invention has a long excited-state lifetime, high intersystem crossing efficiency, and suitable energy level structure, making it an ideal candidate material for photosensitizers and suitable for upconversion luminescence systems and visible light photocatalytic oxidation reactions.

The application belongs to the technical field of biological medicine, and provides a photosensitizer, a targeted delivery nano platform and application. A preparation method of the photosensitizer comprises the following process: a Suzuki coupling reaction is used to synthesize an intermediate with an aldehyde group by taking a brominated or iodinated triphenylamine as a precursor and reacting with boric acid, and then a Knoevenagel condensation reaction is used to convert the terminal aldehyde group into a strong electron-withdrawing dicyanovinyl group by reacting the aldehyde group intermediate with malononitrile, so as to synthesize the photosensitizer PSs. The application takes a structure-optimized photosensitizer (used for generating ROS and inactivating viruses) and a STING agonist (used for activating the STING pathway and inducing cell death) as core treatment components, and takes a rabies virus glycoprotein peptide as a active targeting ligand, so that the "PDT-immune" synergistic inactivation of RABV can be realized.

The application discloses an MMP-2 responsive targeted brain glioma synergistic diagnosis and treatment and immune activation nano probe and a preparation method and application thereof, and relates to the technical field of biological medicine. The probe is formed by assembling an Angiopep-2 targeting peptide, an MMP-2 response sequence, a chemotherapeutic drug and a photosensitizer I-BODIPY, has a hydrodynamic diameter of 10-50 nm, and has excellent biocompatibility. The probe is combined with an LRP1 receptor through the Angiopep-2 to cross the blood-brain barrier, is specifically cut by MMP-2 in a tumor microenvironment to release drugs at a fixed point, integrates the functions of chemotherapy, photothermal / photodynamic therapy and fluorescence imaging, synchronously activates immunogenic cell death and paraptosis, and reshapes an anti-tumor immune microenvironment. The probe can realize precise targeting of brain glioma, synergistic diagnosis and treatment, immune activation and tumor staging evaluation, significantly prolongs the survival period of tumor-bearing mice, and provides a new scheme for glioblastoma diagnosis and treatment.

The present application relates to the field of biological medicine nanomaterials, and particularly relates to a kind of nanocomposite material and its preparation method and application.The preparation method of nanocomposite material provided by the present application, first, by a kind of room temperature fast, green method is synthesized hollow sodium bismuth fluoride carrier, and doping makes it have excellent upconversion luminescence performance, then using the excellent surface area of hollow sodium bismuth fluoride is successfully loaded photosensitizer MC540, clothing mould toxin, finally using DSPE-PEG-FA is modified, obtains nanocomposite material.It can effectively activate tumor cell endogenous calcium overload, induce tumor cell pyroptosis, realize the effect of efficient cancer treatment.

Intraluminal photodynamic therapy (PDT) of a target tumor tissue that is carried out from within a blood vessel is disclosed. The PDT method may be a vascular-targeted photodynamic therapy (VTP) or any other form of PDT where photosensitizer concentration in the blood vessel endothelium is not phototoxic. The PDT of this disclosure is carried out from within a blood vessel in the vicinity of the target tissue or organ with a light-diffusing section of an irradiating optical fiber being positioned within the confines of an inflatable balloon section of a balloon catheter, which is inflated during irradiation to occlude blood flow.

The application provides a high-robustness photoresist for physiological electrodes, a manufacturing method and an in-situ manufacturing method of physiological electrodes, and can prepare two layers of photoresists with an undercut structure by stacking two layers of photoresists on each other, wherein the two layers of photoresists only differ in the concentration of photosensitizers, the concentration difference is adjusted according to the required undercut profile, and the mass percentage components include 3-10% film-forming resin, 90-97% deionized water, 0.1-1% diazo photosensitizer and 0.1-1% surfactant. The surface of a flexible substrate is cleaned by using an ion beam etching technology; a photoresist with low photosensitizer content is spin-coated to obtain a defect-free low-interface-adhesion transferable photoresist film; the photoresist with high photosensitizer content is transferred to the flexible substrate loaded with the photoresist with low photosensitizer content; the flexible substrate loaded with the two layers of photoresists is attached to a hard master mask plate, and is exposed, so that the pattern of the hard master mask plate is transferred to the photoresists, a two-layer stacked photoresist pattern with an undercut structure is formed, high-fidelity replication of the photoetching mask plate structure is realized, and subsequent peeling is facilitated.

The present application relates to a kind of microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma and its preparation method, belong to medical technical field.The microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma, including photosensitizer precursor, anesthetic and solvent, the mass final concentration of the photosensitizer precursor is 15-25 %, the mass final concentration of the anesthetic is 4-6 %, and the photosensitizer precursor is hydrochloric acid aminolevulinic acid.The microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma prepared by the present application adopts the mode of microdroplet injection, solves the three big problems of drug delivery, function preservation and pain control commonly faced in the treatment of different sensitive parts (face, hand, genital organ, tongue), enhances the practicability of the microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma of the present application.

This invention relates to a photosensitizer with a D1-π-A-π-D2 type structure based on asymmetric end-capped donor units. This material is characterized by using 4-(5-(4-(9H-carbazole-9-yl)phenyl)) as donor units (D1) and 5-(4-(diphenylamino)phenyl) as donor units (D2), with isooctylthiophene as the connecting π-bridge, and phenazine as the central acceptor unit (A), specifically naphthiazo[1,2-b][1,2,5]thiadiazo[3,4-g]quinoxaline and [1,2,5]thiadiazo[3,4-i]dithienozo[2,3-a:3',2'-c]phenazine. The photophysical properties of this D1-π-A-π-D2 type photosensitizer were tested, and a novel photosensitizer with high photothermal conversion efficiency and high reactive oxygen species (ROS) yield was developed. The material involved in this invention has near-infrared II region imaging and photothermal in-situ imaging diagnostic functions, and is expected to be used as an organic photosensitizer material for integrated photothermal and photodynamic diagnosis and treatment.

The present application belongs to the technical field of nanometer material preparation, and relates to a kind of nanometer medicine, including medicine carrier and active ingredient, medicine carrier adopts amphiphilic polymer, and active ingredient includes photosensitizer Ce6 and analgesic drug LC. The preparation method of the nanometer medicine is also disclosed, comprising the following steps: weighing Ce6, analgesic drug LC and amphiphilic polymer, dissolving in solvent to obtain a mixed solution; the mixed solution is stirred uniformly, and dialyzed in ultrapure water; the solution obtained by dialysis is constant volume, and filtered to obtain nanometer medicine. The nanometer medicine particle size morphology is regular, the particle size is uniform, has good stability within 7 days, can have good enrichment effect at tumor site, and has good photodynamic therapy effect. Lidocaine and photosensitizer reach the lesion site at the same time through intravenous injection, not only reduce the operation steps, but also target the lesion site, reduce the anxiety of patients because they feel that anesthesia will affect intelligence.

This invention discloses a berberine-dimethylaniline photosensitizer, its preparation method, and its application, belonging to the field of biomedical technology. The method involves sequentially reacting berberine with magnesium methyl bromide via Grignard addition, followed by bromomethylation with N-bromosuccinimide, and basic condensation with dimethylaminobenzaldehyde, then demethylating under high temperature and vacuum to obtain the active berberine-dimethylaniline. Finally, it undergoes weakly alkaline treatment to obtain the inactivated berberine-dimethylaniline. This invention introduces the electron-donating group dimethylaniline onto the berberine backbone, constructing an electron push-pull structure that red-shifts the absorption wavelength, facilitating deeper tissue penetration. Furthermore, this photosensitizer maintains high activity in the weakly acidic microenvironment of tumors while remaining inactive under normal physiological conditions, thereby achieving intelligent "on-off" regulation based on pH differences, improving the safety and precision of photodynamic therapy for tumors.

The application belongs to the field of tumor photodynamic therapy, and discloses a berberine photosensitizer and a preparation method and application thereof, and particularly relates to a berberine compound shown in the following general formula (I). The compound has an aggregation-induced emission property, can efficiently generate active oxygen to kill tumor cells under light conditions, and has good application potential in the field of imaging-guided photodynamic therapy.

This invention discloses a method for preparing a bio-based photosensitive dye synergistic antibacterial wool fabric, belonging to the field of functional textile materials technology. The method first prepares polyethylene glycol-modified molybdenum disulfide, then encapsulates the bio-based photosensitive dye in a zeolite imidazole framework material ZIF-8, and subsequently combines the two to obtain a Bio-Dye@ZIF-8 / PEG-MoS2 synergistic antibacterial component. The wool fabric is then subjected to an amination pretreatment, and the synergistic antibacterial component is loaded onto the surface of the wool fabric, resulting in a wool fabric with both dyeing and antibacterial functions. This method utilizes the porous structure of ZIF-8 to inhibit photosensitizer aggregation and quenching, improves antibacterial efficiency through photodynamic and photothermal synergy, and integrates the dyeing and antibacterial functions of the wool fabric. The resulting wool fabric achieves an inhibition rate of over 99% against Staphylococcus aureus while maintaining good breathability and mechanical properties.

This invention relates to photodynamic therapy, specifically to a class of quinoxaline-fused dihydroporphyrin compounds and their application as photosensitizers in photodynamic therapy. The compounds are those shown in formula (I) and their medically acceptable salts. These compounds have a good soft tissue phototherapy window and can generate singlet oxygen with extremely high quantum yield under light irradiation, making them suitable for photodynamic therapy of deep pathological tissues. They exhibit excellent photodynamic therapy performance and have promising prospects for photodynamic application development.

The application discloses a kind of photochemical reaction long afterglow luminescence photosensitizer materials, nanoparticles and preparation method and application thereof.The photochemical reaction long afterglow luminescence photosensitizer materials are obtained by reacting 3,4-disubstituted maleic anhydride derivatives with isoluminol or isoluminol derivatives containing amino group;The substituent group of the 3,4-disubstituted maleic anhydride derivative is R1 and R2.The photochemical reaction long afterglow luminescence photosensitizer materials of the application realize high signal-to-noise ratio in vivo by photochemical reaction long afterglow luminescence, long-life fluorescent imaging, and have important application prospect in efficient clinical PDT treatment.

This invention provides a photosensitive resin composition and its application. The photosensitive resin composition comprises a combination of a first alkali-soluble resin, a second alkali-soluble resin, and a photosensitizer. The first alkali-soluble resin has a weight-average molecular weight ≤ 5000 and contains at least one structural unit of Formula I, Formula II, or Formula III. The second alkali-soluble resin has a weight-average molecular weight ≥ 6000. The first alkali-soluble resin has a low molecular weight and a specific molecular structure, which imparts a fast alkali solubility rate, enabling it to function as a sensitizer and exhibiting excellent thermal stability. The photosensitive resin composition has significantly improved sensitivity and excellent thermal stability. During its curing process, imide ring closure and cross-linking reactions occur to form a stable structure, thereby improving the heat resistance, stability, and reliability of devices containing it and extending their service life.

This invention provides a method for preparing and applying a chlorophyll-based photosensitizer, belonging to the field of novel photosensitizer preparation technology. The method includes dissolving sodium chlorophyll in water to a concentration of 0.5–8 mM, adding zinc oxide to the sodium chlorophyll solution, stirring in the dark, and then sequentially centrifuging, washing, and drying to obtain a sodium chlorophyll-zinc oxide complex. The combination of semiconductor materials and sodium chlorophyll significantly enhances the photostability of sodium chlorophyll and exhibits good antibacterial activity against plant pathogens.

This invention discloses a miR-141 / near-infrared light dual-response synergistic drug delivery system, relating to the fields of biomedicine and nanomedicine. The system uses DNA-modified gold nanocages as carriers, loading doxorubicin (a chemotherapy drug) and methylene blue (a photosensitizer). H-type DNA nanolocks formed by thiol-modified A and B chains achieve specific recognition of miR-141 and dual response to near-infrared light. miR-141 binding triggers initial unwinding of the nanolocks, followed by complete unwinding and drug release via 808nm near-infrared light irradiation (photothermal effect). A 650nm laser excites methylene blue to generate reactive oxygen species, simultaneously completing quantitative detection of miR-141 (fluorescence / SERS signal complementarity) and synergistic treatment in three modes: chemotherapy + photothermal + photodynamic therapy. In vitro experiments show a miR-141 detection sensitivity of 5.0 × 10⁻⁶. ‑12 M, with a dual-response drug release rate exceeding 60%; in vivo experiments have demonstrated a tumor inhibition rate exceeding 70% and good biocompatibility. This system solves the problems of single-response and separation of diagnosis and treatment in existing delivery systems, and is suitable for precision treatment of miR-141 positive solid tumors such as MCF-7.